Delivery Order SPE2DB24D2100-SPE2DB25FBGFM
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,942.82 to AmerisourceBergen Drug Corp for Alfuzosin HCL ER 10 mg tablets (90-count supply) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count) with a ceiling value of $4,953.94. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a delivery order valued at $1,367.28 to AmerisourceBergen Drug Corp for Alfuzosin HCL ER 10 mg tablets (90-count supply) on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count units) valued at $1,240.25. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The order is scheduled for completion by July 29, 2025, with performance to be executed from AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets in a quantity of 90 tablets. This firm fixed-price delivery order, valued at $1,642.98, is scheduled for completion by September 10, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was awarded without a set-aside designation, indicating it was competitively awarded among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count units) with a ceiling value of $1,541.01. This is a firm fixed-price delivery order with no set-aside designation, completed competitively under open procurement requirements. The contract calls for delivery to Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count units) with a ceiling value of $2,770.72. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation, indicating it was awarded through open competition. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count packages) valued at $2,733.13. This non-competitive, firm fixed-price delivery order is set to be completed by September 9, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a continuation of pharmaceutical supply services under the company's existing...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Alfuzosin ER 10mg (120-count supply) at a firm fixed price of $7,082.16, with completion targeted for September 11, 2025. This non-set-aside competitive award represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Alfuzosin ER 10mg in a quantity of 120 units, with a ceiling value of $1,059.47. The award was made on September 8, 2025, under a firm fixed-price delivery order contract type with no set-aside designation. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of October 3, 2025. This delivery order is issued under...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGFMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Alfuzosin HCL ER 10 mg tablets (90-count units) on September 9, 2025, with a ceiling value of $18,135.41. This firm fixed price delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major pharmaceutical distributor serving federal medical procurement needs. As a critical vendor for military and veteran healthcare systems, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical commodities through its DLA Troop Support Medical contract vehicle, which encompasses brand-name and generic medications, vaccines, and specialized healthcare supplies across multiple therapeutic domains. The Pharmaceutical Prime Vendor Global Program contract structure enables the company to support customers including the Defense Health Agency and U.S. Coast Guard. This delivery order for Alfuzosin—a medication commonly used for urinary symptoms associated with benign prostatic hyperplasia—exemplifies the routine pharmaceutical supply operations conducted under the broader IDC framework to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.1k | 9/9/25 |